We're Now In Pharma's "Top Tier," Says AbbVie CEO
Abbvie ABBV +1.48% chief executive Rick Gonzalez, whose team beat out several more established drug giants in the successful bid for cancer pill maker Pharmacyclics PCYC +0.11%, said today new and existing products will bring “top tier growth through the rest of the decade and beyond.”
Gonzalez’ bold statement, setting the stage for a larger Abbvie, came during this morning’s first quarter call with analysts, predicting bullish growth for a wide range of products, including Humira, the autoimmune treatment facing competition from cheaper biosimilars.
Help employers find you! Check out all the jobs and post your resume<
Gonzalez’ bold statement, setting the stage for a larger Abbvie, came during this morning’s first quarter call with analysts, predicting bullish growth for a wide range of products, including Humira, the autoimmune treatment facing competition from cheaper biosimilars.
Help employers find you! Check out all the jobs and post your resume<